網膜新生血管形成の世界市場-2023年～2030年

概要

網膜新生血管という病的な病気は、目の奥にある光に敏感な組織である網膜に、新しい血管が異常に発生することで定義されます。未治療のままにしておくと、この病気は多くの眼疾患と関連しており、重度の視力障害や失明を引き起こすことさえあります。

このような異常な血管が発達すると、瘢痕化、黄斑浮腫、網膜出血など、視力を著しく損なうさまざまな問題が生じます。さらなる視力低下を食い止めるためには、網膜新生血管の診断と治療が必要です。

網膜新生血管市場は、特に新興国における糖尿病有病率の増加の影響を大きく受けています。網膜新生血管の主な原因は糖尿病性網膜症であり、糖尿病患者の増加とともに治療を必要とする患者数も増加しています。

湿性加齢黄斑変性（AMD）を含む加齢性眼疾患は、高齢化社会でより一般的になっています。これらの疾患によって引き起こされる網膜新生血管を抑制する治療法の必要性は、世界人口の高齢化に伴って高まっています。

市場力学：促進要因

糖尿病網膜症への注目の高まり

糖尿病の微小血管障害として最も一般的な糖尿病網膜症（DR）は、世界で1億人以上が罹患しており、先進国における視覚障害や法定失明の重大な原因となっています。DRは従来、増殖型（PDR）と非増殖型（NPDR）に分類されてきました。NPDRからPDRへの進行は、新生血管の発現によって特徴づけられます。新生血管は、網膜内出血、硬・軟滲出物、綿毛斑、微小動脈瘤、静脈口径異常、網膜内微小血管異常、黄斑および末梢毛細血管非灌流を特徴とします。

VEGFはタイトジャンクションタンパク質のリン酸化を促進し、網膜毛細血管の透過性を増加させる。さらに、トランスサイトーシスの亢進、活性化されたNOSを介したプロセス、オクルディン、カテニン、カドヘリンを含む様々な細胞間分子の誘導変化、トランスサイトーシスの亢進はすべてVEGFに関連した透過性亢進に寄与しています。主にVEGF-Aアイソフォームによって制御されるこれらのVEGF関連現象は、非常に複雑な一連の付加的活性とメディエーターとともに、一般的なDR関連合併症であるDMEを発症させ、進行させる。

網膜障害の硝子体内治療薬としてFDAの承認を受けた最初の薬剤はpegaptanib（Macugen、Eyetech/Pfizer）でした。この物質はVEGF165アイソフォームのヘパリン結合ドメインに優先的に結合するペグ化アプタマーです。

限られた患者の認識

診断や治療開始の遅れは、患者や医療従事者が網膜新生血管の徴候や危険性を知らないことに起因している可能性があります。特に資源の乏しい地域では、眼科専門施設や有資格の眼科医を利用できる場所が限られている場合があり、そのために治療が遅れたり、期待した治療効果が得られなかったりすることがあります。抗VEGF注射などの網膜新生血管の治療には、感染症、網膜剥離、眼圧上昇などのリスクや副作用が伴うことがあります。このような危険性があるため、治療を受けないという選択をする患者もいます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 糖尿病網膜症への注目の高まり
  • 抑制要因
    • 限られた患者意識
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• ロシア・ウクライナ戦争の影響分析
• SWOT分析
• 特許分析
• DMIオピニオン

第6章 COVID-19分析

第7章 疾患タイプ別

• 加齢黄斑変性（AMD）
• 糖尿病網膜症
• 網膜静脈閉塞症
• その他

第8章 治療タイプ別

• 抗VEGF療法
  • ラニビズマブ
  • アフリバーセプト
• 副腎皮質ステロイド
• その他

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• Regeneron Pharmaceuticals Inc.
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Biogen
• Notal Vision, Inc.
• Novartis AG
• Adverum Biotechnologies, Inc.,
• Genentech, Inc.
• Bayer AG
• Others

第13章 付録

Overview

The pathological disease is known as retinal neovascularization is defined by the aberrant development of new blood vessels in the retina, the light-sensitive tissue at the back of the eye. If left untreated, this illness, which is linked to a number of eye conditions, can cause severe vision issues or even blindness.

The development of these aberrant blood vessels can result in a number of problems, including scarring, macular edema, and retinal hemorrhages, which can all seriously impair vision. To stop additional vision loss, retinal neovascularization must be diagnosed and treated in a way.

The retinal neovascularization market is significantly influenced by the increased prevalence of diabetes, particularly in emerging economies. A major contributor to retinal neovascularization is diabetic retinopathy, and the number of patients requiring care grows along with the number of diabetics.

Age-related eye disorders including wet age-related macular degeneration (AMD) are more common in the aging population. The need for treatments to control the retinal neovascularization brought on by these disorders is growing as the world's population ages.

Market Dynamics: Drivers

The Increasing Focus on Diabetic Retinopathy

The most prevalent microangiopathic consequence of diabetes mellitus, diabetes retinopathy (DR), affects more than 100 million people globally and is a significant contributor to visual impairment and legal blindness in developed nations. DR is traditionally divided into proliferative (PDR) and non-proliferative (NPDR) types. The progression from NPDR to PDR is marked by the onset of neovascularization, which is characterized by intraretinal hemorrhages, hard and soft exudates, cotton-wool spots, microaneurysms, venous calibre abnormalities, intraretinal microvascular anomalies, and both macular and peripheral capillary nonperfusion.

VEGF enhances the phosphorylation of tight junction proteins, increasing the permeability of retinal capillaries. Additionally, enhanced transcytosis, activated NOS-mediated processes, induced changes of various intercellular molecules, including occludin, catenins, and cadherins, as well as increased transcytosis all contribute to VEGF-related hyperpermeability. All of these VEGF-related phenomena, which are primarily controlled by VEGF-A isoforms, together with an incredibly complicated series of additional activities and mediators cause DME, a common DR-related complication, to start and progress.

The first medication to receive FDA approval for the intravitreal treatment of retinal disorders was pegaptanib (Macugen, Eyetech/Pfizer). This substance is a pegylated aptamer that binds to the heparin-binding domain of VEGF165 isoform with preference.

Limited Patient Awareness

Delays in diagnosis and the start of treatment may result from patients and healthcare professionals being unaware of the signs and dangers of retinal neovascularization. There may be limited availability to specialist eye care facilities and qualified ophthalmologists in some areas, especially in low-resource settings, which might cause treatment to be delayed or fall short of expectations. Treatments for retinal neovascularization, such as anti-VEGF injections, may come with risks and adverse effects like infection, retinal detachment, and increased intraocular pressure. Some patients may choose not to seek therapy because of these dangers.

Segment Analysis

The global retinal neovascularization market is segmented based on product type, end-user, and region.

The anti-VEGF therapies segment accounted for approximately 48.4% of the market share

Aflibercept (Eylea; Regeneron), ranibizumab (Lucentis; Genentech, California), and bevacizumab (Avastin; Genentech) are the most frequently used VEGF-A pathway treatments available for AMD. The approach to treating wet AMD has been changed by anti-VEGF drugs.

Bevacizumab is a fully humanized immunoglobulin G1 (IgG1) molecule of 148 kDa that binds VEGF-A isoforms under the brand name Avastin from Hoffmann-La Roche. This antibody was initially created for the treatment of cancer. Its intravitreal application for retinal conditions is still regarded as "off-label" therapy. Bevacizumab functions as a pure anti-VEGF antibody, and its major effects are to inhibit the neovascular stimulation and VEGF-induced enhanced vascular permeability. The mechanisms of action are rather straightforward.

Anti-VEGF medications are considered to be the standard of care for treating wet AMD, but in practice, the expenses associated with treating wet AMD frequently make it difficult to achieve the best possible clinical results. The cost of current anti-VEGF medicines may be reduced by the development of biosimilars, which are biologics with equivalent efficacy and safety to reference biologics.

Despite the fact that anti-VEGF treatment is useful and effective for a variety of retinal illnesses, patients and the healthcare system are significantly burdened by the need for repeated intravitreal medication injections due to their high cost and intrusive nature.

Geographical Analysis

Advanced Healthcare Infrastructure

North America has been a dominant force in the global retinal neovascularization market. Between 1,100 and 1,500 newborns in the U.S. experience ROP that is severe enough to call for medical attention. Infants who are born before 31 weeks of pregnancy or who are under 1,500 grams (3.3 lbs) at birth are frequently affected by this rare eye illness. These newborns are at danger of developing aberrant retinal blood vessels (retinal neovascularization), which could result in retinal detachment and irreversible vision loss. Retinal blood vessels are frequently only fully developed after an infant is full-term (9 months of pregnancy). ROP can sometimes improve on its own in mild cases, but in more severe cases, treatment may be necessary to prevent major blindness and visual impairment.

In June 2022, Biogen Inc. and Samsung Bioepis Co., Ltd. Launched BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS (ranibizumab), in the United States. BYOOVIZ is commercially available from July 2022, through significant distributors throughout the U.S. Healthcare provider involvement, promotional activity, cooperation with professional associations, and patient advocacy groups have already begun. In September 2021, the FDA authorized BYOOVIZ for the treatment of myopic choroidal neovascularization, macular edema following retinal vein occlusion, and neovascular (wet) age-related macular degeneration (AMD).

In April 2023, Adverum Biotechnologies, Inc., a clinical-stage company, stated nonclinical data in support of the two doses of ixoberogene soroparvovec (Ixo-vec, formerly known as ADVM-022) being assessed in the Phase 2 LUNA trial as well as the potential for staggered, bilateral administration in the treatment of wet AMD.

COVID-19 Impact Analysis:

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global retinal neovascularization market. There were delays in the detection and treatment of retinal neovascularization and associated eye problems because of lockdowns, restrictions, and patients' anxiety about attending healthcare institutions during the epidemic.

The pandemic may have caused clinical studies for novel therapeutics to be postponed or temporarily stopped, which could have had an impact on the development of new medications and their possible market introduction.

Competitive Landscape

The major global players in the market include: Regeneron Pharmaceuticals Inc., Biogen, Notal Vision, Inc., Novartis AG, Adverum Biotechnologies, Inc., Genentech, Inc., Bayer AG, and Others.

Key Developments

• In February 2023, Regeneron Pharmaceuticals, Inc. declared that the U.S. Food and Drug Administration has authorized EYLEA (aflibercept) Injection to treat preterm infants with retinopathy of prematurity.

Why Purchase the Report?

• To visualize the global retinal neovascularization market segmentation based on disease type, treatment type, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of retinal neovascularization market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global retinal neovascularization market report would provide approximately 55 tables, 56 figures, and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Disease Type
• 3.2. Snippet by Treatment Type
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The Increasing Focus on Diabetic Retinopathy
  • 4.1.2. Restraints
    • 4.1.2.1. Limited Patient Awareness
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Russia-Ukraine War Impact Analysis
• 5.6. SWOT Analysis
• 5.7. Patent Analysis
• 5.8. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Disease Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 7.1.2. Market Attractiveness Index, By Disease Type
• 7.2. Age-Related Macular Degeneration (AMD)*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Diabetic Retinopathy
• 7.4. Retinal Vein Occlusion
• 7.5. Others

8. By Treatment Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.1.2. Market Attractiveness Index, By Treatment Type
• 8.2. Anti- VEGF Therapies*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.2.3. Ranibizumab
  • 8.2.4. Afliberscept
• 8.3. Corticosteroids
• 8.4. Others

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Regeneron Pharmaceuticals Inc.*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Biogen
• 12.3. Notal Vision, Inc.
• 12.4. Novartis AG
• 12.5. Adverum Biotechnologies, Inc.,
• 12.6. Genentech, Inc.
• 12.7. Bayer AG
• 12.8. Others

LIST NOT EXHAUSTIVE.

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us